BIO vs MSFT Stock Comparison
BIO currently leads MSFT in this stock comparison, with AIQ scores of 73 vs 67. The clearest difference is value, while MSFT has the stronger quality profile.
What is the main difference between BIO and MSFT?
BIO leads the current stock comparison as Bio-Rad Laboratories, Inc., with the clearest separation coming from value and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
Bio-Rad Laboratories, Inc. vs Microsoft Corporation
BIO leads
BIO leads by 6 AIQ points, primarily on Value, and the lead has widened from 3 points over 30 sessions.
Fragile: 2 of 5 evidence groups support BIO, its lead is widening, and its current signal state is conflicted.
Bio-Rad Laboratories, Inc.
Microsoft Corporation
The Algovestiq AIQ Score currently favors BIO over MSFT, 73 versus 67 as of Nov 18, 2026. BIO's advantage is driven primarily by stronger value, while MSFT holds the stronger quality profile. BIO also shows the stronger technical structure relative to its 50-day moving average. 2 of 5 covered evidence groups favor BIO today, and the comparison is rated Fragile on stability: only 2 of 5 covered evidence groups agree. BIO lead: Strengthening — the AIQ differential moved from 3 to 6 points over 30 sessions.
Compare Bio-Rad Laboratories, Inc. and Microsoft Corporation across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Total return with distributions reinvested, from daily closes.
Total return comparison
Growth of $10,000, distributions reinvested
Split-adjusted closes; each distribution is reinvested at the close on its ex-dividend date. Taxes and trading costs are not modeled.
Compare BIO and MSFT against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Value80 vs 52BIO +28
- Quality61 vs 65MSFT +4
- Risk Resilience74 vs 71Even
- Momentum79 vs 77Even
2 of 5 evidence groups favor BIO. BIO’s edge is concentrated in value; MSFT keeps a meaningful quality edge.
What changed since the last close
Latest scored session 2026-11-18, compared against the prior scored session 2026-11-17.
Largest factor move: Momentum -1, not enough on its own to move the overall score.
New signals
- MACD Bearish Crossover — bearish, momentum, short horizon
- MACD Histogram Expanding Bearish — bearish, momentum, short horizon
Largest factor move: Momentum -2
No signal started or stopped since the prior session; its 7 active signals are unchanged.
BIO's lead widened by 1 AIQ point in the latest session.
Deeper signal detail for each name lives on its own signals page — BIO and MSFT both carry a full feed there.
The central trade-off
BIO (Bio-Rad Laboratories, Inc.): the stronger current systematic profile, led by value.
MSFT (Microsoft Corporation): the counter-case, on quality, fundamentals — but at materially higher volatility, 36.9% against 31.4%.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
BIOBIO on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
BIOBIO on combined revenue and EPS growth.
Value
BIOBIO on the peer-relative Value factor, by 28 points.
Momentum
EvenThe two are level on Momentum.
Lower downside
BIOBIO carries the lower 1-month annualized volatility.
Analyst upside
EvenAnalyst targets are level or not covered for both names.
AIQ vs Wall Street
Where the systematic read and the analyst consensus line up — and where they do not.
| Measure | BIO | MSFT | Note |
|---|---|---|---|
| Implied upside to target | — | +24.7% | Level |
| Target dispersion | — | +48.9% | Lower is tighter analyst agreement |
| Consensus | Hold | Buy | Context, not a primary driver |
| Analysts covering | 3 | 58 | Higher coverage generally improves confidence |
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
2 of 5 covered evidence groups favor BIO. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | BIO | 73 vs 67 |
| Fundamentals | MSFTon balance | EPS growth 23.3% vs 12.4%; TTM ROE 6% vs 8.1%; gross margin 51.3% vs 67.7%; operating margin 4.6% vs 47.1% — MSFT takes 3 of 4 decided legs, not all of them |
| Valuation | BIO | Value 80 vs 52 |
| Technicals | Even | Price vs 50-day -0.7% vs -2.1%; vs 200-day 15.6% vs 18.7% |
| Risk Resilience | Even | Risk Resilience 74 vs 71 |
| Analyst expectations | Not covered | Not covered |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of BIO and MSFT and are excluded from the count.
AIQ Decision Stability
The conclusion is sensitive to small changes. Treat the lead as provisional and watch the flip conditions below.
- The AIQ gap is moderate at 6 points.
- Only 2 of 5 covered evidence groups agree. (argues the conclusion is provisional)
- The leader's advantage has been widening. (supports the conclusion holding)
- The lead has been steady session to session. (supports the conclusion holding)
- The leader is throwing conflicting signals. (argues the conclusion is provisional)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on BIO.
How the comparison changed
120 daily snapshots · Jun 1 – Nov 18BIO lead: Strengthening — the AIQ differential moved from 3 to 6 points over 30 sessions.
- Today
- BIO +6
- 73 vs 67
- 7 sessions ago
- BIO +6
- 75 vs 69
- 30 sessions ago
- BIO +3
- 72 vs 69
- 90 sessions ago
- BIO +11
- 73 vs 62
The lead has not changed hands in this window.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
3 bullish / 2 bearish / 1 neutral, conflicted
Only BIO
- ATR Expansion - Breakout Mode — neutral, volatility, short horizon (3.56%)
- MACD Bearish Crossover — bearish, momentum, short horizon
- TRIX Bullish Signal — bullish, momentum, short horizon
4 bullish / 1 bearish / 2 neutral, conflicted
Only MSFT
- Bollinger Band Squeeze — neutral, volatility, short horizon (7.6%)
- ADX Trend Weakening — neutral, trend, medium horizon
- OBV Bullish Divergence — bullish, volume, medium horizon (-1.0%)
- Uptrend Structure Active — bullish, trend, long horizon
Both carry 3 more signals that do not separate them: Golden Cross Active, EMA Ribbon Expansion Bullish, MACD Histogram Expanding Bearish.
BIO leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +3.34%, AIQ 0 points).
Price is up while the AIQ Score moved down 1 points over the same session — price and model disagree (price +0.4%, AIQ -1 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1MSFT closes the Value gap — currently 28 points behind, the largest single contributor to BIO's edge.
- 2MSFT's Bollinger Band Squeeze turns directional — it is neutral today and would confirm a change in trend.
- 3BIO's conflicting signal state resolves bearish — it currently carries 3 bullish and 2 bearish rules at once.
- 4A market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
MSFT leads on balance| Metric | BIO | MSFT |
|---|---|---|
| Revenue growth (YoY) | 0.8% | 8.6% |
| EPS growth (YoY) | 23.3% | 12.4% |
| Gross margin | 51.3% | 67.7% |
| Operating margin | 4.6% | 47.1% |
| Return on equity (TTM) | 6% | 8.1% |
| Debt to equity | 0.18 | 0.28 |
Performance
BIO leads 4 of 6 windows| Metric | BIO | MSFT |
|---|---|---|
| 1 week (5 sessions) | -4% | -1.3% |
| 1 month (20 sessions) | 3.6% | -1% |
| 3 months (63 sessions) | 3.1% | 9.1% |
| 6 months (126 sessions) | 48% | 24.2% |
| Year to date | 20.9% | 8.3% |
| 1 year (252 sessions) | 11.9% | 2.5% |
Technicals
Split| Metric | BIO | MSFT |
|---|---|---|
| RSI (14) | 45.4 | 48.8 |
| ADX (14) | 12.9 | 17 |
| Price vs 50-day | -0.7% | -2.1% |
| Price vs 200-day | 15.6% | 18.7% |
| Volatility (1M, annualized) | 31.4% | 36.9% |
Risk
Split| Metric | BIO | MSFT |
|---|---|---|
| Beta | 0.73 | 1.02 |
| Sharpe ratio | 0.47 | 0.17 |
| Sortino ratio | 0.69 | 0.26 |
| Max drawdown | -27.2% | -30.8% |
| Current drawdown | -6.1% | -5.7% |
| Annualized volatility | 36.2% | 34% |
| Value at risk (95%) | -3% | -2.9% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, BIO or MSFT?
On the Algovestiq AIQ Score, BIO is the stronger of the two as of Nov 18, 2026, scoring 73 against MSFT's 67. The edge comes from value. MSFT is not without a case — it holds the better quality profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is BIO or MSFT the better buy right now?
BIO carries the stronger systematic profile as of Nov 18, 2026, and the comparison is rated Fragile — 2 of 5 covered evidence groups agree. A Fragile rating means the conclusion is sensitive: only 2 of 5 covered evidence groups agree. Treat the lead as provisional.
Why does the AIQ Score favor BIO over MSFT?
The composite weights Quality, Value, Momentum and Risk Resilience. BIO leads Value by 28 points; MSFT leads Quality by 4 points. Where the two split, the factor with the larger weight carries the result.
Which has more analyst upside, BIO or MSFT?
Analyst price targets imply not covered upside for BIO and +24.7% for MSFT. The model and the Street agree here, which is a broader base of evidence than either alone. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, BIO or MSFT?
BIO is the better-valued of the two on the peer-relative Value factor. BIO on the peer-relative Value factor, by 28 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, BIO or MSFT?
BIO on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, BIO or MSFT?
The two are level on Momentum. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, BIO or MSFT?
BIO is the more resilient of the two, so the other name carries the higher downside risk. BIO carries the lower 1-month annualized volatility. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is BIO more profitable than MSFT?
MSFT leads on the comparable margin measures — gross margin 51.3% vs 67.7%; operating margin 4.6% vs 47.1%; ttm roe 6% vs 8.1%.
Is BIO's lead over MSFT getting stronger or weaker?
BIO lead: Strengthening — the AIQ differential moved from 3 to 6 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-06-01 and 2026-11-18. The lead has not changed hands in that window.
What would change the BIO vs MSFT verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: MSFT closes the Value gap — currently 28 points behind, the largest single contributor to BIO's edge; MSFT's Bollinger Band Squeeze turns directional — it is neutral today and would confirm a change in trend; BIO's conflicting signal state resolves bearish — it currently carries 3 bullish and 2 bearish rules at once; a market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.
What do the current signals say about BIO and MSFT?
BIO: 3 bullish / 2 bearish / 1 neutral, conflicted. MSFT: 4 bullish / 1 bearish / 2 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on BIO is Golden Cross Active (bullish, long horizon). On MSFT it is Golden Cross Active (bullish, long horizon).
Compare BIO and MSFT with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.